T1 mapping predicts outcome in patients with a systemic right ventricle: A sub-analysis of the SERVE study

Clicks: 15
ID: 327824
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #47 of 80 articles by views in European Heart Journal Open

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Aims In patients with a systemic right ventricle (sRV), the sRV is faced with an increased afterload compared to a right ventricle in sub-pulmonary position leading to the development of fibrosis followed by ventricular dysfunction. Cardiac magnetic resonance (CMR) T1 mapping (T1), and its derived parameter like the extracellular volume (ECV), allow quantification of interstitial fibrosis. The SERVE study, a multicentric, placebo-controlled trial evaluated the effect of tadalafil in sRV patients. The aim of this sub-analysis of the SERVE trial was to evaluate a) the relationship of T1 mapping parameters to the clinical composite endpoint of hospitalization for heart failure, clinically relevant arrythmias and all-cause mortality and b) its evolution over time, correlation to CMR functional parameters and the impact of study treatment. Methods and results Patients included in the SERVE trial underwent a 1.5T CMR at baseline, one and three-year follow-up. For each CMR exam, native and post-contrast T1, as well as ECV, were calculated. In addition, late gadolinium enhancement (LGE) imaging was performed. CMR were available for sixty patients. Native sRV T1 and ECV above the 75th percentile, but not LGE, were associated with the clinical composite endpoint. There was no significant change and no influence of Tadalafil treatment on sRV T1 and ECV. Conclusion T1 mapping as a non-invasive biomarker of the degree of myocardial fibrosis predicts outcome in patients with sRV and should be incorporated in risk stratification in these patients. PDE-5 inhibitor tadalafil appears to have no impact on the development of interstitial or macroscopic fibrosis.
Reference Key
openalex_W7211974724 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Odile Burdet, Kerstin Wustmann, Barbara Burkhardt, Emanuela R Valsangiacomo Buechel, Jean‐Paul Vallée, Judith Bouchardy, Matthias Greutmann, Markus Schwerzman, H. Gabriel, Dominik Stambach, Daniel Tobler, Juerg Schwitter, Tobias Rutz
Are you one of these authors? Claim your profile
Journal European Heart Journal Open
Year 2026
DOI
10.1093/ehjopen/oeag138
URL
https://doi.org/10.1093/ehjopen/oeag138
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.